Holen Sie sich die Stockscreener-App
658.48
0.62%
-4.14
Schlusskurs vom Vortag:
$662.62
Offen:
$658
24-Stunden-Volumen:
1.68M
Relative Volume:
1.95
Marktkapitalisierung:
$71.99B
Einnahmen:
$14.20B
Nettoeinkommen (Verlust:
$4.41B
KGV:
17.20
EPS:
38.28
Netto-Cashflow:
$3.54B
1W Leistung:
-1.26%
1M Leistung:
-5.98%
6M Leistung:
-42.49%
1J Leistung:
-31.98%
1-Tages-Spanne:
$651.06
$661.00
1-Wochen-Bereich:
$651.06
$679.83
52-Wochen-Spanne:
$642.00
$1,211.20
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Firmenname
Regeneron Pharmaceuticals Inc
Sektor
Branche
Telefon
(914) 847-7000
Adresse
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Vergleichen Sie REGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
658.48 | 71.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
503.20 | 129.22B | 11.02B | -535.60M | -978.00M | -2.20 |
|
ARGX
Argen X Se Adr
|
615.02 | 37.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
283.34 | 36.68B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
251.98 | 27.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-05 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Herabstufung | UBS | Buy → Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-09-24 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Eingeleitet | Bernstein | Outperform |
| 2024-01-12 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Bestätigt | Oppenheimer | Perform |
| 2023-06-28 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Hochstufung | Jefferies | Hold → Buy |
| 2023-03-23 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Hochstufung | Cowen | Market Perform → Outperform |
| 2023-01-20 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Hochstufung | Jefferies | Underperform → Hold |
| 2022-09-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Eingeleitet | Jefferies | Underperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-01-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-12-07 | Fortgesetzt | Cowen | Market Perform |
| 2021-12-06 | Eingeleitet | Goldman | Buy |
| 2021-11-19 | Fortgesetzt | BMO Capital Markets | Outperform |
| 2021-11-05 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-01-25 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-10-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Hochstufung | SunTrust | Hold → Buy |
| 2020-05-26 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-04-17 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Eingeleitet | The Benchmark Company | Hold |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-02-26 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Hochstufung | Jefferies | Hold → Buy |
| 2020-02-11 | Hochstufung | Argus | Hold → Buy |
| 2019-12-24 | Eingeleitet | Raymond James | Mkt Perform |
| 2019-12-16 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Eingeleitet | SunTrust | Hold |
| 2019-11-07 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
Alle ansehen
Regeneron Pharmaceuticals Inc Aktie (REGN) Neueste Nachrichten
Forefront Wealth Management Inc. Acquires New Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
American Century Companies Inc. Sells 30,949 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Virtu Financial LLC Has $3.06 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Summit Global Investments - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Teacher Retirement System of Texas - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
Madison Investment Advisors LLC Takes $4.59 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Short Interest in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Grows By 16.8% - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Royal London Asset Management Ltd. - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Position Increased by Envestnet Portfolio Solutions Inc. - MarketBeat
DCF Advisers LLC Has $6.34 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Commonwealth of Pennsylvania Public School Empls Retrmt SYS Cuts Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Advisors Asset Management Inc. Sells 443 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
iA Global Asset Management Inc. Decreases Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Avantax Advisory Services Inc. - MarketBeat
Commonwealth Equity Services LLC Sells 967 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
11,358 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Acquired by Generali Asset Management SPA SGR - MarketBeat
Nikko Asset Management Americas Inc. Sells 2,730 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Genmab, NHS England, Pistoia Alliance and Regeneron Win Bio-IT World Innovative Practices Awards - PR Newswire
First Week of November 21st Options Trading For Regeneron Pharmaceuticals (REGN) - Nasdaq
Blueshift Asset Management LLC Boosts Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Vinva Investment Management Ltd Buys 1,182 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
3 Reasons to Sell REGN and 1 Stock to Buy Instead - Financial Content
Short Interest in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Increases By 16.8% - Defense World
Cibc World Markets Corp Grows Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Age-Related Macular Degeneration Therapeutics Market - openPR
Kazazian Asset Management LLC Invests $399,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Harvest Fund Management Co. Ltd Acquires 1,366 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Xponance Inc. Boosts Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Thrivent Financial for Lutherans Has $89.18 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Corient Private Wealth LLC Sells 4,349 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Intact Investment Management Inc. Acquires Shares of 500 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
To Register Unwavering Growth Of Age-related Vision - openPR
Refractory Multiple Myeloma Treatment Market Size in 7MM - openPR
Greykasell Wealth Strategies Inc. Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Achmea Investment Management B.V. Reduces Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
AGF Management Ltd. Purchases 942 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Trading Down 1.8%Here's Why - MarketBeat
Where are the Opportunities in (REGN) - Stock Traders Daily
Price Over Earnings Overview: Regeneron Pharmaceuticals - Benzinga
Regeneron Pharmaceuticals (REGN): Among the Best Biotech Stocks to Buy According to Billionaires - Insider Monkey
Bowen Hanes & Co. Inc. Cuts Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
PGGM Investments Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Jim Cramer Wants You to ‘Own’ Regeneron Pharmaceuticals (REGN) Shares - Yahoo Finance
Regeneron Pharmaceuticals (NasdaqGS:REGN) Shares Dip 1% Despite Positive Dupixent Trial Results - Simply Wall St
Diabetic Retinopathy Treatment Market Growth, Latest Insights - openPR
Amgen’s Bufferless Eylea Biosimilar Again Knocks Back Regeneron’s Injunctive Bid - Citeline
The Biotech Stocks Tackling the World’s Most Common Cancer - Value the Markets
Natixis Advisors LLC Sells 7,064 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Swiss National Bank Sells 15,300 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Bronte Capital Management Pty Ltd. Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Finanzdaten der Regeneron Pharmaceuticals Inc-Aktie (REGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Regeneron Pharmaceuticals Inc-Aktie (REGN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| McCourt Marion | EVP Commercial |
Nov 01 '24 |
Option Exercise |
381.40 |
1,000 |
381,400 |
13,931 |
| McCourt Marion | EVP Commercial |
Nov 01 '24 |
Sale |
844.61 |
1,000 |
844,610 |
12,931 |
0.32%
4.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):